Javascript must be enabled to continue!
Positive and negative regulation of FcεRI signaling by SHP‐1
View through CrossRef
SHP‐1 is a cytoplasmic tyrosine phosphatase and, in mast cells, has been shown to negatively regulate the initial signaling triggered by high affinity receptors for IgE (FcεRI). To clarify the molecular mechanisms of SHP‐1 in mast cells, we generated bone marrow‐derived mast cells (BMMCs) from SHP‐1‐deficient motheaten (me) and control (wt) mice and examined downstream signaling events and final outputs following FcεRI crosslinking. FcεRI‐induced tyrosine phosphorylation of SLP‐76 and LAT was increased in me‐derived BMMCs. The activity of Syk that is responsible for the phosphorylation of SLP‐76 and LAT was comparable in both BMMCs, implying that SLP‐76 and LAT might be substrates of SHP‐1 in mast cells. Lack of SHP‐1 expression resulted in enhanced activation of mitogen activated protein kinases, Erk, JNK, and p38, and transcription of cytokine genes such as TNFα and IL‐6, in good accordance with the previous implication of SHP‐1 as a negative regulator. In contrast, FcεRI‐induced calcium mobilization was severely impaired in me‐derived BMMCs. Whereas wt‐BMMCs showed sprolonged increase in calcium flux upon high intensity stimulation, BMMCs derived from me mice demonstrated decreased and transient responses. In addition, me‐BMMCs exhibited diminished calcium flux at low intensity stimulation. Thapsigargin induced similar level of calcium flux in both BMMCs, indicating that BMMCs lacking SHP‐1 expression are still capable of mobilizing calcium. These studies revealed that SHP‐1 not only regulates FcεRI‐signaling negatively but can act as a positive regulator in mast cells. The experiments to clarify possible molecular mechanisms for the positive regulation of calcium signaling by SHP‐1 are currently under study.
Title: Positive and negative regulation of FcεRI signaling by SHP‐1
Description:
SHP‐1 is a cytoplasmic tyrosine phosphatase and, in mast cells, has been shown to negatively regulate the initial signaling triggered by high affinity receptors for IgE (FcεRI).
To clarify the molecular mechanisms of SHP‐1 in mast cells, we generated bone marrow‐derived mast cells (BMMCs) from SHP‐1‐deficient motheaten (me) and control (wt) mice and examined downstream signaling events and final outputs following FcεRI crosslinking.
FcεRI‐induced tyrosine phosphorylation of SLP‐76 and LAT was increased in me‐derived BMMCs.
The activity of Syk that is responsible for the phosphorylation of SLP‐76 and LAT was comparable in both BMMCs, implying that SLP‐76 and LAT might be substrates of SHP‐1 in mast cells.
Lack of SHP‐1 expression resulted in enhanced activation of mitogen activated protein kinases, Erk, JNK, and p38, and transcription of cytokine genes such as TNFα and IL‐6, in good accordance with the previous implication of SHP‐1 as a negative regulator.
In contrast, FcεRI‐induced calcium mobilization was severely impaired in me‐derived BMMCs.
Whereas wt‐BMMCs showed sprolonged increase in calcium flux upon high intensity stimulation, BMMCs derived from me mice demonstrated decreased and transient responses.
In addition, me‐BMMCs exhibited diminished calcium flux at low intensity stimulation.
Thapsigargin induced similar level of calcium flux in both BMMCs, indicating that BMMCs lacking SHP‐1 expression are still capable of mobilizing calcium.
These studies revealed that SHP‐1 not only regulates FcεRI‐signaling negatively but can act as a positive regulator in mast cells.
The experiments to clarify possible molecular mechanisms for the positive regulation of calcium signaling by SHP‐1 are currently under study.
Related Results
Abstract 1773: The tyrosine phosphatase, SHP-2, is involved in regulating PD-L1 expression in non-small cell lung cancer
Abstract 1773: The tyrosine phosphatase, SHP-2, is involved in regulating PD-L1 expression in non-small cell lung cancer
Abstract
Immune checkpoint inhibitors (ICIs), specifically those which target the T-cell surface receptor Programmed Cell Death-1 (PD-1) and its ligand, Programme...
SR-BI regulates the synergistic mast cell response by modulating the plasma membrane-associated cholesterol pool
SR-BI regulates the synergistic mast cell response by modulating the plasma membrane-associated cholesterol pool
Abstract
The high-affinity IgE receptor FcεRI is the fundamental mast cell (MC) receptor responsible for the involvement of MCs in IgE-associated...
Differential Mast Cell Outcomes Are Sensitive to FcεRI-Syk Binding Kinetics
Differential Mast Cell Outcomes Are Sensitive to FcεRI-Syk Binding Kinetics
Abstract
Crosslinking of IgE-bound FcεRI triggers multiple cellular responses, including degranulation and cytokine production. Signaling is dependent on recruitmen...
Activating PTPN11 Mutants Promote Myelomonocytic Differentiation Due to Altered Hematopoietic Lineage-Specific Transcription Factor Expression.
Activating PTPN11 Mutants Promote Myelomonocytic Differentiation Due to Altered Hematopoietic Lineage-Specific Transcription Factor Expression.
Abstract
Juvenile myelomonocytic leukemia (JMML) is a lethal disease of young children characterized by pathologic overproduction of myelomonocytic cells. Mutations ...
SR‐BI regulates the synergistic mast cell response by modulating the plasma membrane‐associated cholesterol pool
SR‐BI regulates the synergistic mast cell response by modulating the plasma membrane‐associated cholesterol pool
Abstract
The high‐affinity IgE receptor FcεRI is the mast cell (MC) receptor responsible for the involvement of MCs in IgE‐associated allergi...
ChREBP Rather than SHP Regulates Hepatic VLDL Secretion
ChREBP Rather than SHP Regulates Hepatic VLDL Secretion
The regulation of hepatic very-low-density lipoprotein (VLDL) secretion plays an important role in the pathogenesis of dyslipidemia and fatty liver diseases. VLDL is controlled by ...
Predictors of False-Negative Axillary FNA Among Breast Cancer Patients: A Cross-Sectional Study
Predictors of False-Negative Axillary FNA Among Breast Cancer Patients: A Cross-Sectional Study
Abstract
Introduction
Fine-needle aspiration (FNA) is commonly used to investigate lymphadenopathy of suspected metastatic origin. The current study aims to find the association be...
Abstract 1799: Src homology region 2 domain-containing phosphatase-1 (SHP-1) is overexpressed in hepatocellular carcinoma.
Abstract 1799: Src homology region 2 domain-containing phosphatase-1 (SHP-1) is overexpressed in hepatocellular carcinoma.
Abstract
Purpose. The aim of this study is to investigate the relationship between SHP-1 phosphatase activity and clinicopathological characteristics in hepatocellul...

